These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9074526)

  • 1. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
    Stein R; Goldenberg DM; Thorpe SR; Mattes MJ
    J Nucl Med; 1997 Mar; 38(3):391-5. PubMed ID: 9074526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
    Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ
    Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
    Stein R; Chen S; Haim S; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2636-41. PubMed ID: 9406718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
    Stein R; Govindan SV; Mattes MJ; Shih LB; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
    Govindan SV; Stein R; Qu Z; Chen S; Andrews P; Ma H; Hansen HJ; Griffiths GL; Horak ID; Goldenberg DM
    Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine.
    Stein R; Govindan SV; Chen S; Reed L; Spiegelman H; Griffiths GL; Hansen HJ; Goldenberg DM
    Crit Rev Oncol Hematol; 2001; 39(1-2):173-80. PubMed ID: 11418314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R; Juweid M; Mattes MJ; Goldenberg DM
    Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
    Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved iodine radiolabels for monoclonal antibody therapy.
    Stein R; Govindan SV; Mattes MJ; Chen S; Reed L; Newsome G; McBride BJ; Griffiths GL; Hansen HJ; Goldenberg DM
    Cancer Res; 2003 Jan; 63(1):111-8. PubMed ID: 12517786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
    Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
    Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manipulation of blood clearance to optimize delivery of residualizing label-antibody conjugates to tumor cells in vivo.
    Stein R; Goldenberg DM; Ong GL; Thorpe SR; Mattes MJ
    J Nucl Med; 1997 Sep; 38(9):1392-400. PubMed ID: 9293796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
    Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):813-23. PubMed ID: 9240651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.
    Behr TM; Sgouros G; Vougiokas V; Memtsoudis S; Gratz S; Schmidberger H; Blumenthal RD; Goldenberg DM; Becker W
    Int J Cancer; 1998 May; 76(5):738-48. PubMed ID: 9610734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts.
    Buchsbaum DJ; Lawrence TS; Roberson PL; Heidorn DB; Ten Haken RK; Steplewski Z
    Int J Radiat Oncol Biol Phys; 1993 Mar; 25(4):629-38. PubMed ID: 8454481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
    Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
    Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.